HPV16 Genomic Status Stratifies Risk of Disease Recurrence in Oropharyngeal Squamous Cell Carcinoma
Authors:
- Victor MalassignéVMVictor Malassigné
- Julien PuechJPJulien Puech
- Sandrine ImbeaudSISandrine Imbeaud
- Anne AuperinAAAnne Auperin
- Caroline EvenCECaroline Even
- Dac Hung NguyenDNDac Hung Nguyen
- Maxime WackMWMaxime Wack
- Bastien RanceBRBastien Rance
- Léa BenyakarLBLéa Benyakar
- Léa PicavetLPLéa Picavet
- Victor EuzenVEVictor Euzen
- Laurent BélecLBLaurent Bélec
- 15 July 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (19) , 4434-4447
Abstract
Purpose: A subset of patients with human papillomavirus (HPV)–positive oropharyngeal squamous cell carcinoma (OPSCC) develops disease recurrence despite generally favorable outcomes. Reliable biomarkers for risk stratification remain lacking. We investigated whether comprehensive viral genomic profiling refines prognostic classification. Experimental Design: Tumor samples from 100 patients with p16-positive and HPV DNA–positive OPSCC enrolled in 2 independent cohorts were analyzed using targeted viral capture sequencing. Viral genotype, sublineage, single-nucleotide variation, virus–host integration sites, viral structural variants (SV), clonality, and viral copy number were characterized. Associations with cumulative incidence of progression, progression-free survival (PFS), and overall survival were assessed at 60 months. Results: HPV16 was detected in 94 tumors, 83 of which belonged to the HPV16_A1 sublineage. Within this sublineage, 20 tumors harbored strictly episomal viral genomes, whereas 63 exhibited integration and/or viral SV. No progression events occurred in the strictly episomal HPV16_A1 subgroup, whereas 12 occurred among HPV16_A1 tumors with an integration and/or SV. At 60 months, no progression events were observed in strictly episomal HPV16_A1 tumors compared with a 23.1% cumulative incidence of progression in HPV16_A1 tumors with an integration and/or SV. Previously reported high-risk single-nucleotide variants and a novel upstream regulatory region variant were associated with worse PFS. Integration sites were enriched in open chromatin and promoter regions and clustered within viral E2 and E4 genes. Conclusions: Within HPV16_A1 tumors, viral genomic architecture defines clinically distinct subgroups. Strictly episomal (wild-type) genomes identify a low-risk population, whereas integration and SV characterize higher-risk disease.Keywords
All Related Versions
Funding Information
- Agence Nationale de Recherches sur le Sida et les Hépatites Virales
- Human Cancer Immunome program
This publication has 40 references indexed in Scilit:
- Clonal origin and early lineage divergence in adenosquamous carcinomaCell Reports, 2026
- The combined HPV16-E2/E6/E7 T cell response in oropharyngeal cancer predicts superior survivalCell Reports Medicine, 2023
- Human papilloma virus integration sites and genomic signatures in head and neck squamous cell carcinomaMolecular Oncology, 2022
- Genetic variation within the human papillomavirus type 16 genome is associated with oropharyngeal cancer prognosisAnnals of Oncology, 2022
- SearcHPV: A novel approach to identify and assemble human papillomavirus–host genomic integration events in cancerCancer, 2021
- Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2020
- HPV circulating tumoral DNA quantification by droplet‐based digital PCR: A promising predictive and prognostic biomarker for HPV‐associated oropharyngeal cancersInternational Journal of Cancer, 2019
- Patients with integrated HPV16 in head and neck cancer show poor survivalOral Oncology, 2018
- Human papillomavirus integration pattern and demographic, clinical, and survival characteristics of patients with oropharyngeal squamous cell carcinomaHead & Neck, 2016
- Analysis of the integration of human papillomaviruses in head and neck tumours in relation to patients' prognosisInternational Journal of Cancer, 2015